Global immunology drug market was valued at $6,225.0 million in 2025 and is projected to reach $9,240.9 million by 2035, growing at a CAGR of 4.1% during the forecast period (2026-2035). The rising prevalence of autoimmune and inflammatory disorders represents a fundamental driver supporting expansion of the global immunology drug market. According to National Institute of Allergy and Infectious Diseases indicates that autoimmune diseases affect nearly 8% of the US population, emphasizing the growing patient pool requiring long-term therapeutic management. Centers for Disease Control and Prevention surveillance further shows that more than 53.2 million US adults reported diagnosed arthritis between 2019 and 2021, reflecting a significant disease burden linked to immunology treatment demand. Increasing incidence across indications such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease is strengthening clinical reliance on monoclonal antibodies, fusion proteins, and immunosuppressants. Higher diagnosis rates supported by improved screening and awareness programs are expanding the addressable patient population across specialty care settings. Chronic disease progression and the need for continuous immune modulation are contributing to sustained therapy utilization across both hospital and outpatient environments. These epidemiological factors remain central to long-term revenue forecasting within immunology therapeutics.
Browse the full report description of “Immunology Drug Market Size, Share & Trends Analysis Report by Drug Class (Monoclonal Antibody (mAb), Immunosuppressants, Polyclonal Antibody (pAb), Fusion Proteins, and Others), by Disease Indication (Rheumatoid Arthritis, Cancer, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Others) Forecast Period, (2026–2035)” at https://www.omrglobal.com/industry-reports/immunology-drug-market
Healthcare systems are increasingly prioritizing targeted immune therapies to manage complex autoimmune conditions, reinforcing demand across multiple drug classes. According to the World Health Organization, rheumatoid arthritis prevalence is rising in aging populations, with women affected two to three times more often than men, emphasizing the need for specialized biologic treatment approaches. As per, National Center for Biotechnology Information data, in 2021, there were 17.9 million prevalence cases, 1 million incidence cases, and 3.08 million DALYs globally. Expanding clinical guidelines encouraging early biologic use are accelerating adoption of monoclonal antibody therapies and fusion protein platforms across rheumatology and gastroenterology practices. Pharmaceutical manufacturers continue to invest in targeted mechanisms such as cytokine inhibition and Fc-receptor modulation to address unmet clinical needs. Growing integration of precision medicine and biomarker-based therapy selection is enhancing treatment outcomes and supporting consistent prescribing trends. These healthcare and clinical developments collectively position immunology drugs as a critical therapeutic segment within the broader specialty pharmaceutical landscape.
Innovation Leaders Transforming the Immunology Drug Market
The key players in the immunology drug include AbbVie Inc., Johnson & Johnson (Innovative Medicine), Roche Holding AG, Pfizer Inc., Sanofi S.A., among others. These players focus on advancing monoclonal antibodies, fusion proteins, and other targeted immunotherapies to improve treatment outcomes in autoimmune and inflammatory diseases. Ongoing investment in biologics development, biosimilars, and precision medicine continues to strengthen innovation and support market expansion.
Market Coverage
Key questions addressed by the report.
Global Immunology Drug Market Report Segment
By Drug Class
By Disease Indication
Global Immunology Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunology-drug-market